| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2017-01-23 |
复牌提示：
2017-01-23 08:09:22 停牌，复牌日期 2017-01-24 00:00:01
|
| 2016-11-25 |
股东大会：
将于2016-12-19召开股东大会
会议内容 ▼▲
- 1. Approval, pursuant to Section 320 of the Israeli Companies Law, of the merger of Macrocure with M-Co. Merger Sub, Ltd., or Merger Sub, an Israeli company that is a wholly-owned subsidiary of Leap, including the approval of: (i) the merger transaction, whereby Merger Sub will merge with and into Macrocure, with Macrocure surviving and becoming a wholly-owned subsidiary of Leap; (ii) the Agreement and Plan of Merger, or merger agreement, dated as of August 29, 2016, by and among Macrocure, Merger Sub and Leap; (iii) the consideration to be received by Macrocure’s shareholders in the Merger, consisting of a fraction of a share of common stock of Leap (to be determined based on an exchange ratio described in the merger agreement, which is subject to adjustment based on Macrocure’s net cash (as defined in the merger agreement) as of the effective time of the merger) for each ordinary share of Macrocure held as of immediately prior to the effective time of the merger; (iv) the conversion of each outstanding option and warrant to purchase one ordinary share of Macrocure into an option or warrant (as applicable) to purchase a fraction of a share of Leap common stock (to be determined by multiplying one ordinary share by the exchange ratio), at an increased exercise price (to be determined by dividing the existing exercise price by the exchange ratio), subject to accelerated vesting upon the effective time in the case of each outstanding option, and otherwise subject to the remaining terms and conditions under the existing option or warrant; (v) the entry by certain of Macrocure’s significant shareholders into a registration rights agreement with Leap, providing them with the right to request that their shares be included in a registration statement that Leap may in the future otherwise be filing for the potential sale of Leap common stock they will receive upon the effectiveness of the merger; and (vi) all other transactions and arrangements contemplated by the merger agreement.
2. Subject to, and effective upon, the consummation of the merger, Macrocure’s purchase, in accordance with the merger agreement, of a “tail” insurance policy for its officers and directors that will provide coverage at substantially the same level as under Macrocure’s existing insurance for its officers and directors, until the seventh anniversary of the merger’s effectiveness.
3. Approval of a grant of options to purchase 36,662 ordinary shares of Macrocure to each of Katherine Wolf and Yuval Yanai, directors of Macrocure, at an exercise price equal to the closing market price of the ordinary shares of Macrocure on the date of the shareholder meeting, which will vest in an accelerated manner upon the effectiveness of the merger (or an alternate M&A transaction).
4. Approval of certain compensatory measures for Nissim Mashiach, Macrocure’s CEO, including: (i) an amendment to his existing options to purchase ordinary shares of Macrocure so that the exercise period thereunder post-termination of employment does not expire upon consummation of the merger or an alternate M&A transaction; and (ii) effective upon, and subject to, the consummation of the merger (or alternate M&A transaction): (a) a grant to the CEO of options to purchase 150,000 ordinary shares of Macrocure, at an exercise price equal to the closing market price of the ordinary shares of Macrocure on the date of the shareholder meeting, which will vest in an accelerated manner at the effectiveness of the merger, (b) payment of a $300,000 cash bonus to the CEO, subject to Macrocure’s implied value being assessed at a certain level for purposes of the merger (or other M&A transaction), which requirement may be waived at the discretion of the Chairman of the Board, after consultation with the compensation committee of the board of directors, and (c) a one-time “make whole” payment to the CEO, payable upon the consummation of the merger (or other M&A transaction) and equal to $10,000 per month for each month from December 2015 through and including the month during which the merger (or other M&A transaction) is consummated.
|
| 2016-11-25 |
详情>>
股本变动：
变动后总股本1793.21万股
|
| 2015-12-09 |
股东大会：
将于2016-01-13召开股东大会
会议内容 ▼▲
- 1.The proposed re-election of each current member of Macrocure’s board of directors for an additional one year term (other than the statutory external directors, who serve a three-year term pursuant to the Israeli Companies Law).
2.Ratification of the re-appointment of Somekh Chaikin, Certified Public Accountants (Isr.), a member firm of KPMG International, as the Company’s independent registered public accounting firm for 2015 and the additional period until the next annual meeting.
3.The second agenda item for the meeting— ratification of the appointment of Somekh Chaikin— has been approved by the audit committee of the Company’s Board of Directors and by the Board, and is being brought before the shareholders for approval pursuant to requirements under the Israeli Companies Law.
|
| 2015-02-19 |
股东大会：
将于2015-03-11召开股东大会
会议内容 ▼▲
- 1. Approval, in accordance with the requirements of the Israeli Companies Law, 5759-1999, or the Companies Law, of the payment of an amended compensation package to Mr. Nissim Mashiach, the Company's Chief Executive Officer, or the CEO, for the 2015 year;
2. Approval, in accordance with the requirements of the NASDAQ Listing Rules and the Companies Law, respectively, of amendments to the Company’s 2013 Share Incentive Plan that will (a) increase the number of shares available for issuance thereunder by 400,000, and (b) provide for acceleration of vesting of options granted to our directors from time to time upon the consummation of an acquisition of (or other similar transaction involving) the Company.
|
| 2014-12-04 |
股东大会：
将于2014-12-30召开股东大会
会议内容 ▼▲
- 1.The Meeting is being called for the purpose of voting on the approval of a compensation policy for the Company’s executives and directors, in accordance with the requirements of the Israeli Companies Law, 5759-1999, or the Companies Law.
2.Transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.
|
| 2014-10-01 |
股东大会：
将于2014-11-05召开股东大会
会议内容 ▼▲
- 1. to ratify the election of each of (a) Ms. Katherine Wolf and (b) Mr. Yuval Yanai as an external director of the Company, subject to, and in accordance with, the provisions of the Israeli Companies Law, 5759-1999, or the Companies Law;
2. conditioned upon the approval of Proposal 1 above, to ratify the approval of the payment of compensation to each of the external directors that consists of (i) an annual fee of $30,000 and (ii) a one-time grant of options to purchase 36,662 of the Company’s ordinary shares, nominal value NIS 0.01 per share, or ordinary shares, at an exercise price of $10.00 per share, subject to a four year vesting period and the other terms of the Company’s 2013 Share Incentive Plan.
|